PHIO earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -0.74. Updated 2026-07-23.
Phio Pharmaceuticals (PHIO) Research Hub
Phio Pharmaceuticals (PHIO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.03 USD (0.00%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.74, market cap 0.01B. This hub links to the full technical, earnings and options research available for PHIO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.03 USD (0.00%) |
| 52-week range | 0.84 USD – 1.24 USD |
| Trend regime | Range |
| 14-day RSI | 48.8 (Neutral) |
| Trailing P/E | -0.74 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for PHIO
Covered Call on PHIO: how it works, illustrative setup around the real 1.03 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PHIO: how it works, illustrative setup around the real 1.03 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PHIO: how it works, illustrative setup around the real 1.03 USD price, max profit/loss, breakeven and when to use it. Educational.
PHIO technical analysis: range, last 1.03 USD, RSI 48.8, 52w range 0.84 USD–1.24 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PHIO in?
Phio Pharmaceuticals (PHIO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PHIO in an uptrend or downtrend?
As of 2026-09-11, PHIO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PHIO's trailing P/E ratio?
PHIO's trailing P/E is -0.74, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does PHIO next report earnings?
PHIO is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.36 USD.